<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902512</url>
  </required_header>
  <id_info>
    <org_study_id>A1481267</org_study_id>
    <nct_id>NCT00902512</nct_id>
  </id_info>
  <brief_title>Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations</brief_title>
  <official_title>Relative Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations In Healthy Volunteers Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the pharmacokinetics of sildenafil following single doses of sildenafil CT administered with
      and without water is similar relative to the conventional oral tablet of sildenafil
      administered with water.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-T and Cmax of sildenafil</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of sildenafil</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax and half-life of sildenafil</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and vital signs</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Males</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Viagra® 100 mg tablet, administered with water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 100 mg CT administered with water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 100 mg CT administered without water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>Viagra® 100 mg tablet, administered with water single dose</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blood samples for the analysis of sildenafil in plasma</intervention_name>
    <description>Blood samples for the analysis of sildenafil in plasma</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>Sildenafil 100 mg CT administered with water single dose</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples for the analysis of sildenafil in plasma</intervention_name>
    <description>Blood samples for the analysis of sildenafil in plasma</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>Sildenafil 100 mg CT administered without water single dose</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples for the analysis of sildenafil in plasma</intervention_name>
    <description>Blood samples for the analysis of sildenafil in plasma</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only healthy male volunteers in the 18-40 age range will be included.

          -  At the selection visit allowed normal range for vital signs will be: Blood pressure
             (with the subject sitting down) 90-130mm Hg systolic and 60-90

          -  The volunteers' health condition will be determined from their complete clinical
             history by doctors at the clinical research site and lab test results by certified
             clinical laboratories mm Hg diastolic, heart rate 55-100 bpm , respiratory rate 14-20
             respirations per minute.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal
             allergies at time of dosing) disease or clinical findings at Screening.

          -  Treatment with a PDE-5 inhibitor within the 4 days preceding the first dose of study
             medication

          -  History of hypersensitivity to sildenafil citrate or any components of its
             formulations
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Col. Arenal Tepepan</city>
        <state>Mexico D.F.</state>
        <zip>14610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481267&amp;StudyName=Study%20Of%20Bioavailability%20Of%20Two%20Sildenafil%20100mg%20Oral%20Tablet%20Formulations%0A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <last_update_submitted>May 30, 2011</last_update_submitted>
  <last_update_submitted_qc>May 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

